AstraZeneca : Forxiga met primary endpoint in T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed to date -October 04, 2023 at 06:54 am EDT

Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga compared with patients receiving...

Related Keywords

Israel ,Cambridge ,Cambridgeshire ,United Kingdom ,Naim Shehadeh ,Astrazeneca ,Rambam Health Care Campus ,Nasdaq ,Executive Vice President ,Biopharmaceuticals Business Unit ,Annual Meeting ,European Association ,New England Journal ,Rare Diseases ,Markets ,